CERENOME, INC. 10-Q

Item 5. Other Information On May 12, 2026, the Company filed a Certificate of Correction (the “Certificate of Correction”) to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Amendment”) that was previously filed on April 1, 2026. The Certificate of Amendment erroneously stated the number of authorized shares of common stock, par value $0.001 per share, of the Company (“Common Stock”) as 200,000,000 (two hundred million). As corrected by the Certificate of Correction, the total number of authorized shares of Common Stock is two billion (2,000,000,000). 34 Table of Contents Item 6. Exhibits EXHIBIT INDEX PLUS THERAPEUTICS, INC. Exhibit Number Exhibit Title Filed with this Form 10-Q Incorporated by Reference Form File No. Date Filed 3.1 Composite Certificate of Incorporation 10-K 001-34375 Exhibit 3.1 03/11/2016 3.2 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375 Exhibit 3.1 05/10/2016 3.3 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375 Exhibit 3.1 05/23/2018 3.4 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375 Exhibit 3.1 07/29/2019 3.5 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375 Exhibit 3.1 08/06/2019 3.6 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375 Exhibit 3.1 04/28/2023 3.7 Certificate of Amendment to the Certificate of Incorporation, as amended 8-K 001-34375 Exhibit 3.1 05/02/2025 3.8 Certificate of Amendment to the Amended and Restated Certificate of Incorporation, filed with the Delaware Secretary of State on April 1, 2026 X 3.9 Certificate of Correction to the Amended and Restated Certificate filed with the Delaware Secretary of State on May 12, 2026 X 3.10 Amended and Restated Bylaws of Plus Therapeutics, Inc. 8-K 001-34375 Exhibit 3.1 09/21/2021 3.11 Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock 8-K 001-34375 Exhibit 3.1 11/28/2017 3.12 Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock 8-K 001-34375 Exhibit 3.1 07/25/2018 3.13 2020 Stock Incentive Plan, as amended and restated on May 14, 2026 X 4.1 Description of Securities 10-K 001-34375 Exhibit 4.1 03/30/2020 4.2 Form of Common Stock Certificate 10-K 001-34375 Exhibit 4.33 03/09/2018 4.3 Form of Pre-Funded Warrant 8-K 001-34375 Exhibit 4.1 05/09/2024 4.4 Form of Amendment and Restatement of the May 2024 Series A Warrant 10-Q 011-34375 Exhibit 4.7 08/14/2024 4.5 Form of Amendment and Restatement of the May 2024 Series B Warrant 10-Q 011-34375 Exhibit 4.8 08/14/2024 4.6 Form of Pre-Funded Warrant 8-K 011-34375 Exhibit 4.1 02/18/2025 35 Table of Contents 4.7 Form of Warrant issued pursuant to the Securities Purchase and Exchange Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc. and the purchasers named therein 8-K 001-34375 Exhibit 4.2 02/18/2025 4.8 Form of Pre-Funded Warrant 8-K 001-34375 Exhibit 4.1 03/04/2025 4.9 Form of Amended March 2025 Series B Warrant 8-K 001-34375 Exhibit 4.1 06/17/2025 4.10 Form of Warrant, dated January 15, 2026 8-K 001-34375 Exhibit 4.1 01/16/2026 31.1* Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-1.04(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 31.2* Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 32.1* Certifications Pursuant to 18 U.S.C. Section 1350/ Securities Exchange Act Rule 13a-14(b), as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002 X 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document X 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents X 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) X * In accordance with Item 601(b)(32)(ii) of Regulation S‑K and SEC Release No. 34‑47986, the certifications furnished in Exhibits 31.1, 31.2 and 32.1 hereto are deemed to accompany this Form 10‑Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the Company specifically incorporates them by reference. 36 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PLUS THERAPEUTICS, INC. By: /s/ Marc H. Hedrick Dated: May 15, 2026 Marc H. Hedrick President & Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) By: /s/ Andrew Sims Dated: May 15, 2026 Andrew Sims Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer and Principal Accounting Officer) 37